Literature DB >> 20490735

Critical variables associated with nonbiodegradable osmotically controlled implants.

Jeremy C Wright1.   

Abstract

Osmotically controlled implants yield precise zero-order drug delivery kinetics and are utilized in a number of applications. The implants deliver drugs for extended periods (weeks to years) and exhibit good in vivo/in vitro correlation. This paper reviews critical variables associated with these implants, with a focus on release rate testing. The extended-duration kinetics can be problematic when attempting to test for >70% cumulative delivery. An innovative scheme based on the scientific principles of operation of the system is described to ensure > 70% delivery at the target rate and duration for the DUROS Viadur (leuprolide acetate) implant.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20490735      PMCID: PMC2895447          DOI: 10.1208/s12248-010-9199-8

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  5 in total

1.  An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer.

Authors:  J C Wright; S Tao Leonard; C L Stevenson; J C Beck; G Chen; R M Jao; P A Johnson; J Leonard; R J Skowronski
Journal:  J Control Release       Date:  2001-07-10       Impact factor: 9.776

2.  Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations.

Authors:  F Theeuwes; S I Yum
Journal:  Ann Biomed Eng       Date:  1976-12       Impact factor: 3.934

3.  Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs.

Authors:  M J Cukierski; P A Johnson; J C Beck
Journal:  Int J Toxicol       Date:  2001 Nov-Dec       Impact factor: 2.032

4.  Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer.

Authors:  J E Fowler; M Flanagan; D M Gleason; I W Klimberg; J E Gottesman; R Sharifi
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

5.  Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer.

Authors:  J E Fowler; J E Gottesman; C F Reid; G L Andriole; M S Soloway
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

  5 in total
  6 in total

Review 1.  Long-term delivery of protein therapeutics.

Authors:  Ravi Vaishya; Varun Khurana; Sulabh Patel; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2014-09-24       Impact factor: 6.648

Review 2.  Accelerated in-vitro release testing methods for extended-release parenteral dosage forms.

Authors:  Jie Shen; Diane J Burgess
Journal:  J Pharm Pharmacol       Date:  2012-03-08       Impact factor: 3.765

3.  Future of sustained protein delivery.

Authors:  Ravi Vaishya; Ashim K Mitra
Journal:  Ther Deliv       Date:  2014-11

4.  Trabecular and cortical bone are unaltered in response to chronic lipopolysaccharide exposure via osmotic pumps in male and female CD-1 mice.

Authors:  Kirsten N Bott; Jenalyn L Yumol; Elena M Comelli; Panagiota Klentrou; Sandra J Peters; Wendy E Ward
Journal:  PLoS One       Date:  2021-02-05       Impact factor: 3.240

Review 5.  Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape.

Authors:  Alexey Fayzullin; Alesia Bakulina; Karen Mikaelyan; Anatoly Shekhter; Anna Guller
Journal:  Bioengineering (Basel)       Date:  2021-12-09

6.  Elastic Bioresorbable Polymeric Capsules for Osmosis-Driven Delayed Burst Delivery of Vaccines.

Authors:  Kerr D G Samson; Eleonore C L Bolle; Mariah Sarwat; Tim R Dargaville; Ferry P W Melchels
Journal:  Pharmaceutics       Date:  2021-03-23       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.